Form 4: KORU Medical Director Manko Jr. Receives Stock Grant

Joseph M. Manko, Jr., a Director and 10% owner of KORU Medical Systems, Inc., received a grant of 3,472 common shares for his board service.

Summary

• Joseph M. Manko, Jr., a Director and 10% owner of KORU Medical Systems, Inc. (KRMD), was granted 3,472 shares of common stock.
• The shares were granted to Horton Capital Partners Fund, LP (HCPF) as consideration for Mr. Manko's service as a Director for the quarter ended March 31, 2026.
• The transaction occurred on March 31, 2026, with a price of $0 per share, indicating a stock grant.
• Following this transaction, the beneficial ownership attributed to the reporting persons, primarily through Horton Capital Partners Fund, LP, is 5,065,970 shares of common stock.
• The filing clarifies the relationships between Mr. Manko, Horton Capital Management, LLC (HCM), Horton Capital Partners, LLC (HCP), and HCPF, noting that Mr. Manko is the managing member of HCM and HCP, and HCP is the general partner of HCPF.
• Reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine and expected insider transaction, reflecting ongoing director compensation and alignment of interests. It's not a major catalyst but indicates continued engagement from a significant shareholder.

Positives

• Director Joseph M. Manko, Jr. received a grant of 3,472 shares of common stock for his service, aligning his interests with shareholders.
• The grant demonstrates ongoing compensation for board service, indicating continued engagement of a 10% owner and director.

Future Outlook

This filing is a report of a past transaction and does not contain forward-looking statements or guidance regarding KORU Medical Systems, Inc.'s future performance or strategic direction.

Management Comments

• The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.
• Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose.

Industry Context

StockSavvy.ai notes that director stock grants are a common practice in the medical device industry, aligning the interests of board members with long-term shareholder value. This particular grant to a 10% owner and director reinforces their continued involvement and vested interest in KORU Medical Systems, Inc.'s performance.

Comparison to Industry Standards

• StockSavvy.ai observes that director compensation in the form of equity grants is a standard practice across publicly traded companies, including those in the medical technology sector.
• While the specific value of the grant (3,472 shares at $0 price, implying market value at grant date) is not detailed, such grants are typically benchmarked against peer companies like Insulet Corporation (PODD) or Tandem Diabetes Care (TNDM) for similar board roles, ensuring competitive compensation that incentivizes long-term performance.
• The grant size is relatively small compared to the total beneficial ownership, suggesting it's a routine quarterly compensation rather than a significant new investment.

Related Party Transactions

• The grant of 3,472 shares to Horton Capital Partners Fund, LP for Joseph M. Manko, Jr.'s director service is a related party transaction, as Mr. Manko is a managing member of entities controlling HCPF and also a director of KORU Medical Systems, Inc.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a significant director and 10% owner with other shareholders, potentially fostering long-term value creation.
• Management: Reinforces the compensation structure for board members.

Key Dates

Recommendation

This Form 4 filing reports a routine stock grant to a director for board service, which is a standard compensation practice. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. The transaction itself, while aligning director interests with shareholders, is not a significant catalyst for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

KORU Medical Systems, KRMD, Form 4, SEC filing, beneficial ownership, stock grant, director compensation, Joseph M. Manko Jr., Horton Capital, insider transaction